Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266053 | 1.00 | CTSK (0.44) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL5115478 | 0.88 | CTSS (0.44) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL14266062 | 0.87 | CTSS (0.43) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL5115874 | 0.87 | CTSS (0.43) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL8382063 | 0.79 | MEN1 (0.50) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL24822539 | 0.78 | CTSS (0.50) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL22469527 | 0.78 | CTSS (0.50) | MEN1KMT2ACTSSSYKCTSL | |
| SCHEMBL22648546 | 0.78 | CTSS (0.50) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL22636318 | 0.78 | CTSS (0.50) | CTSKMEN1KMT2ACTSSSYK | |
| SCHEMBL22636320 | 0.78 | CTSS (0.50) | CTSKMEN1KMT2ACTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007021793-A1 | MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | APP, BACE1, PSEN1 | CTSK 2077/4885MEN1 2986/4885KMT2A 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.